drugset
drugset / Trial / NCT05181735

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735 ↗

Phase 1/2 Recruiting 150 enrolled Groupe Francophone des Myelodysplasies Celgene Corporation · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA

Timeline

Start
2022-05-18
Primary completion
2028-12-19
Completion
2029-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic 0.8 mg/kg Subcutaneous
Subject Luspatercept Protein / enzyme biologic 1.33 mg/kg Subcutaneous
Subject Luspatercept Protein / enzyme biologic 1.75 mg/kg Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 30000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 60000 iu Subcutaneous

Indications

myelodysplastic syndrome